HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Powder/Liquid Delivery Twist: A Consumer-Health Market Shaker?

This article was originally published in The Rose Sheet

Executive Summary

Exclusive online-only content>>>Amerigo Labs is making the New Shaker delivery device – backed by 25 years of market experience in Europe – available in the U.S. as a potentially game-changing technology for manufacturers of drugs, dietary supplements, energy drinks, food and personal-care products. For nutricosmetics firms that market ingestible powder-based products, the packaging innovation could help differentiate offerings from competitors’ products.

You may also be interested in...

Nutricosmetics Firms’ Science, Innovation May Win Over “Trusting” Youth

Exclusive online-only content>>>In a Datamonitor global survey of consumers between the ages of 18 and 34, 41% of respondents found nutricosmetic claims to be “somewhat or completely trustworthy,” signaling opportunity in a category that has been limited in part by consumer skepticism. Datamonitor researcher Aleksandrina Yotova profiles winning innovations and strategies in the niche nutricosmetics segment.

Interview: Fugate Attracted By UrgentRx Focus On Branding, Unique Positioning

Ron Fugate sees UrgentRx not only using some of the strongest marketing strategies he’s known for building a successful consumer health care product brand, but also making headway in new areas important to driving sales for new products.

Alacer Sale Underscores Value-Add Of Best Practices

Best practices help establish a firm’s appeal as an acquisition target, illustrated by the case of Pfizer’s acquisition of Emergen-C maker Alacer.`

Related Content

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts